Sylvia Becker-Dreps1, Anne M Butler2, Leah J McGrath3, Kim A Boggess4, David J Weber5, Dongmei Li6, Michael G Hudgens7, J Bradley Layton8. 1. Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: sbd@unc.edu. 2. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. 3. NoviSci, LLC, Durham, North Carolina. 4. Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 6. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 7. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 8. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; RTI Health Solutions, Research Triangle Park, North Carolina.
Abstract
INTRODUCTION: It is recommended that all pregnant women in the U.S. receive tetanus, diphtheria, acellular pertussis (Tdap) immunization to prevent infant pertussis. This study's objective was to examine the clinical effectiveness of prenatal Tdap, and whether effectiveness varies by gestational age at immunization. METHODS: A nationwide cohort study of pregnant women with deliveries in 2010-2014 and their infants was performed. Commercial insurance claims data were analyzed in 2016-2017 to identify Tdap receipt by the pregnant women, and hospitalizations and outpatient visits for pertussis in their infants until the infants reached 18 months of age. Pertussis occurrence was compared between infants of mothers who received prenatal Tdap (overall and stratified by gestational age at administration) and infants of unvaccinated mothers. RESULTS: There were 675,167 mother-infant pairs in the cohort. Among infants whose mothers received prenatal Tdap, the rate of pertussis was 43% lower (hazard ratio=0.57, 95% CI=0.35, 0.92) than infants whose mothers did not receive prenatal or postpartum Tdap; this reduction was consistent across pertussis definitions (hazard ratio for inpatient-only pertussis=0.32, 95% CI=0.11, 0.91). Pertussis rates were also lower for infants whose mothers received Tdap during the third trimester. Infants whose mothers received Tdap at <27 weeks of gestation did not experience reductions in pertussis rates (hazard ratio for pertussis=1.10, 95% CI=0.54, 2.25). CONCLUSIONS: Infants of mothers who received prenatal Tdap experienced half the rate of pertussis as compared with infants of unimmunized mothers. These results do not provide evidence to support changing the currently recommended timing of Tdap administration in pregnancy.
INTRODUCTION: It is recommended that all pregnant women in the U.S. receive tetanus, diphtheria, acellular pertussis (Tdap) immunization to prevent infant pertussis. This study's objective was to examine the clinical effectiveness of prenatal Tdap, and whether effectiveness varies by gestational age at immunization. METHODS: A nationwide cohort study of pregnant women with deliveries in 2010-2014 and their infants was performed. Commercial insurance claims data were analyzed in 2016-2017 to identify Tdap receipt by the pregnant women, and hospitalizations and outpatient visits for pertussis in their infants until the infants reached 18 months of age. Pertussis occurrence was compared between infants of mothers who received prenatal Tdap (overall and stratified by gestational age at administration) and infants of unvaccinated mothers. RESULTS: There were 675,167 mother-infant pairs in the cohort. Among infants whose mothers received prenatal Tdap, the rate of pertussis was 43% lower (hazard ratio=0.57, 95% CI=0.35, 0.92) than infants whose mothers did not receive prenatal or postpartum Tdap; this reduction was consistent across pertussis definitions (hazard ratio for inpatient-only pertussis=0.32, 95% CI=0.11, 0.91). Pertussis rates were also lower for infants whose mothers received Tdap during the third trimester. Infants whose mothers received Tdap at <27 weeks of gestation did not experience reductions in pertussis rates (hazard ratio for pertussis=1.10, 95% CI=0.54, 2.25). CONCLUSIONS:Infants of mothers who received prenatal Tdap experienced half the rate of pertussis as compared with infants of unimmunized mothers. These results do not provide evidence to support changing the currently recommended timing of Tdap administration in pregnancy.
Authors: Merryn Voysey; Dominic F Kelly; Thomas R Fanshawe; Manish Sadarangani; Katherine L O'Brien; Rafael Perera; Andrew J Pollard Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: Bahaa Abu Raya; Isaac Srugo; Aharon Kessel; Michael Peterman; David Bader; Ron Gonen; Ellen Bamberger Journal: Vaccine Date: 2014-08-28 Impact factor: 3.641
Authors: Anne M Butler; J Bradley Layton; Dongmei Li; Michael G Hudgens; Kim A Boggess; Leah J McGrath; David J Weber; Sylvia Becker-Dreps Journal: Obstet Gynecol Date: 2017-04 Impact factor: 7.661
Authors: Abbey J Hardy-Fairbanks; Stephanie J Pan; Michael D Decker; David R Johnson; David P Greenberg; Kathryn B Kirkland; Elizabeth A Talbot; Henry H Bernstein Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Alba Vilajeliu; Laia Ferrer; Jordina Munrós; Anna Goncé; Marta López; Josep Costa; José M Bayas Journal: Vaccine Date: 2016-06-11 Impact factor: 3.641
Authors: Tami H Skoff; Amy E Blain; James Watt; Karen Scherzinger; Melissa McMahon; Shelley M Zansky; Kathy Kudish; Paul R Cieslak; Melissa Lewis; Nong Shang; Stacey W Martin Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Lourdes R A Vaz-de-Lima; Helena Keico Sato; Eder Gatti Fernandes; Ana Paula Sayuri Sato; Lucia C Pawloski; Maria Lucia Tondella; Cyro A de Brito; Expedito J A Luna; Telma Regina M P Carvalhanas; Euclides A de Castilho Journal: Vaccine Date: 2019-05-29 Impact factor: 3.641
Authors: Annalisa L Post; Shuk Hang Li; Madison Berry; Hannah Itell; David R Martinez; Guanhua Xie; Sallie R Permar; Geeta K Swamy; Genevieve G Fouda Journal: Vaccine Date: 2020-05-29 Impact factor: 3.641
Authors: C Mary Healy; Marcia A Rench; Laurie S Swaim; E O'Brian Smith; Haleh Sangi-Haghpeykar; Marsenia H Mathis; Monte D Martin; Carol J Baker Journal: JAMA Date: 2018-10-09 Impact factor: 56.272
Authors: Miranda K Kiefer; Rebecca Mehl; Kara M Rood; Katherine Germann; Divya Mallampati; Tracy Manuck; Maged M Costantine; Courtney D Lynch; William A Grobman; Kartik K Venkatesh Journal: Vaccine Date: 2022-09-21 Impact factor: 4.169